Welcome to the website of the New Diagnostics Working Group
The New Diagnostics Working Group (NDWG) is one of the seven working groups of the Stop TB Partnership. It supports the Partnership in its goal of eliminating tuberculosis (TB), in particular by promoting the development and evaluation of new TB diagnostic tools. The NDWG is a network of experts representing stakeholders from academia, NGOs, multilaterals and governmental institutions, TB high-burden countries, industry, and the patient community.
New Diagnostics Working Group Annual Meeting
Wednesday, 26 October 2016, 9:00 - 12:30
Arena and Convention Centre, Liverpool, UK
At its 2015 Annual Meeting, the New Diagnostics Working Group (NDWG) launched three task forces with to goal of advancing the priorities in TB diagnostics research and development to support the targets of the End TB strategy and the Global Plan to End TB.
This year, we will review progress made since our last annual meeting with a particular focus on the achievements of our Task Force on Tests for progression of latent tuberculosis infection (LTBI) to active disease. The task force coordinator and members will report on the outcomes of an expert workshop convened by the NDWG in July and present newer understanding of the evolving concept of LTBI diagnosis, as well as advanced drafts of the Target product profile (TPP) for a test of progression of LTBI and of the Framework for evaluation of novel LTBI tests.
Additional presentations will consider the use of existing molecular tests and the perspectives of next generation sequencing for detection of drug resistance in high TB burden countries, and share a recent overview of the biomarker pipeline for TB detection at the point-of-care level, including for paediatric TB.
NDWG launches consultation on draft TPP for a test of progression of LTBI
The New Diagnostics Working Group and its Task Force on tests for progression of LTBI to active disease have recently launched an online consultation to gather input on a draft Target Product Profile (TPP) for a test of progression of latent tuberculosis infection (LTBI).
Reactivation of LTBI is the source of the vast majority of new TB cases in low transmission areas. As global TB incidence declines, preventing progression from LTBI to active TB will be crucial for cutting transmission and reaching the goal of TB elimination. The introduction of targeted and cost-effective treatment of individuals with LTBI requires a diagnostic test to identify the small proportion of latently infected persons who will progress to active disease.
A prognostic test for determining the risk of progression from LTBI to active disease is currently unavailable. To support the development of this new test, FIND has defined a draft TPP with contribution from the NDWG LTBI Task Force and other experts in the field. This document will provide guidance to diagnostic developers as to the key characteristics that the test needs to fulfill in order to meet requirements.
The NDWG is conducting an online survey to gather input from a group of stakeholders representing researchers, endemic countries, governmental and non-governmental organizations, test developers and the patient community. Participants will have the opportunity to evaluate the key performance and operational characteristics as defined in the TPP in order to build large consensus. Results will be discussed by an expert group which will be convened by the NDWG Task Force on LTBI on July 1st 2016 in Milan, Italy, in order to finalize the TPP and submit the document to WHO for endorsement.